GoodRx Holdings, Inc. reported a modest increase in revenue for the second quarter of 2025, reaching $203.1 million, up 1% from $200.6 million in the same period last year. For the first half of 2025, total revenue was $406.0 million, a 2% increase compared to $398.5 million in the first half of 2024. The company achieved a net income of $12.8 million for the quarter, translating to a net income margin of 6.3%, compared to $6.7 million and a 3.3% margin in the prior year. For the six-month period, net income was $23.9 million, significantly higher than $5.7 million in the previous year.
The financial performance reflects a mixed landscape for GoodRx, with prescription transactions revenue declining by 3% year-over-year to $143.1 million, primarily due to a 14% decrease in Monthly Active Consumers. This decline was attributed to broader changes in the retail pharmacy landscape, including store closures and reduced claims volume from integrated savings programs. Conversely, revenue from pharma manufacturer solutions surged by 32% to $35.0 million, driven by organic growth and increased market penetration.
In terms of operational metrics, GoodRx reported a total of 5.7 million Monthly Active Consumers for the quarter, down from 6.6 million a year earlier. The company also noted a decrease in subscription plans, with 668,000 active plans as of June 30, 2025, compared to 696,000 a year prior. The company’s total assets decreased to $1.32 billion from $1.39 billion at the end of 2024, while total liabilities rose to $675.7 million from $663.4 million.
Strategically, GoodRx made a significant acquisition in January 2025, purchasing the assets of VCRx for $30 million, which is expected to enhance its prescription savings offerings. The company continues to navigate challenges in the retail pharmacy sector, including the impact of rising copays and changes in Medicaid funding. Looking ahead, GoodRx anticipates a potential revenue impact of $35 million to $40 million in 2025 due to these market conditions but remains optimistic about long-term growth prospects. The company ended the quarter with $281.3 million in cash and cash equivalents, providing a solid liquidity position to support its operations and strategic initiatives.
About GoodRx Holdings, Inc.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.